Versartis Inc. (NASDAQ:VSAR) saw unusually-high trading volume on Thursday . Approximately 107,230 shares changed hands during trading, an increase of 46% from the previous session’s volume of 73,214 shares.The stock last traded at $11.71 and had previously closed at $11.37.

VSAR has been the subject of several analyst reports. Citigroup Inc. set a $23.00 target price on Versartis and gave the company a “buy” rating in a report on Thursday. Canaccord Genuity set a $28.00 target price on Versartis and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research raised Versartis from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Wednesday, August 3rd. Morgan Stanley reaffirmed a “hold” rating on shares of Versartis in a report on Saturday, April 30th. Finally, Credit Suisse Group AG reaffirmed a “sell” rating and set a $9.00 target price on shares of Versartis in a report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Versartis currently has an average rating of “Buy” and a consensus target price of $17.80.

The firm’s market cap is $345.63 million. The firm’s 50-day moving average is $10.92 and its 200-day moving average is $9.32.

Versartis (NASDAQ:VSAR) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.03. On average, equities research analysts predict that Versartis Inc. will post ($3.20) EPS for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.